Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

Abstract Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drivers of the cell
cycle and are required for the initiation and progression of various malignancies …

Mitotic cell division increases tumour mutation burden and copy number load, predictive
markers of the clinical benefit of immunotherapy. Cell division correlates also with genomic …

Prostate cancers are considered to be immunologically 'cold'tumors given the very few
patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of …

Cancer therapies that target epigenetic repressors can mediate their effects by activating
retroelements within the human genome. Retroelement transcripts can form double …

The past decade has seen the emergence of immunotherapy as a prime approach to cancer
treatment, revolutionizing the management of many types of cancer. Despite the promise of …

DNA methylation inhibitors have become the mainstay for treatment of certain
haematological malignancies. In addition to their abilities to reactivate genes, including …

Immunotherapy is revolutionizing the management of multiple solid tumors, and early data
have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 …

Human endogenous retroviruses (HERVs) are abundant sequences that persist within the
human genome as remnants of ancient retroviral infections. These sequences became fixed …

Chromatin regulators play a broad role in regulating gene expression and, when gone awry,
can lead to cancer. Here, we demonstrate that ablation of the histone demethylase LSD1 in …